Last --
Change Today 0.00 / 0.00%
Volume 0.0
GLENMARK On Other Exchanges
Symbol
Exchange
GLENMARK is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

glenmark pharmaceuticals ltd (GLENMARK) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GLENMARK PHARMACEUTICALS LTD (GLENMARK)

Related News

No related news articles were found.

glenmark pharmaceuticals ltd (GLENMARK) Related Businessweek News

No Related Businessweek News Found

glenmark pharmaceuticals ltd (GLENMARK) Details

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products. The company’s products include Crofelemer, an anti diarrheal drug for symptomatic relief of non-infectious diarrhoea in patients with HIV/AIDS on anti retro viral therapy; GRC 17536 for neuropathic pain and respiratory disorders; and GRC 27864, an orally bioavailable inhibitor of mPGES-1 to treat chronic inflammatory conditions, which is in Phase I trial. Its products also comprise Vatelizumab (GBR 500) that is in Phase II study for multiple sclerosis; GBR 900, which is in is Phase I trial for the treatment of chronic pain targeting TrkA, the receptor of nerve growth factor; and GBR 830, an anti-OX40 monoclonal antibody for autoimmune disorders. In addition, the company is involved in the formulations business that focuses on therapeutic areas, such as dermatology, anti-infectives, respiratory, cardiac, diabetes, gynecology, CNS, and oncology. It has operations in India, Latin America, Europe, the United States, and internationally. Glenmark Pharmaceuticals Limited was founded in 1977 and is headquartered in Mumbai, India.

11,000 Employees
Last Reported Date: 07/1/14
Founded in 1977

glenmark pharmaceuticals ltd (GLENMARK) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: 57.1M
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 16.3M
Director of Corporate Affairs, Executive Dire...
Total Annual Compensation: 18.3M
Compensation as of Fiscal Year 2014.

glenmark pharmaceuticals ltd (GLENMARK) Key Developments

Glenmark Pharmaceuticals Ltd. Announces Resignation of Hocine Sidi Said, Director

Glenmark Pharmaceuticals Ltd. announced that Mr. Hocine Sidi Said, Director of the Company has resigned from the Board with effect from November 25, 2014.

Glenmark Pharmaceuticals Announces Resignation of Hocine Sidi as Director

Glenmark Pharmaceuticals announced that Hocine Sidi, Director of the company has resigned from the Board with effect from November 25, 2014.

Glenmark Pharmaceuticals Ltd. Reports Unaudited Standalone and Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2014

Glenmark Pharmaceuticals Ltd. reported unaudited standalone and consolidated earnings results for the second quarter and six months ended September 30, 2014. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 681.313 million against INR 583.026 million a year ago. Total income from operations was INR 693.156 million against INR 585.373 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 119.359 million against INR 105.299 million a year ago. Profit from ordinary activities before tax was INR 129.070 million against INR 119.899 million a year ago. Net profit for the period was INR 116.427 million against INR 106.948 million a year ago. Basic and diluted earnings per share before and after extraordinary activities were INR 4.29 against INR 3.91 a year ago. For the six months, on standalone basis, the company reported net sales/income from operations of INR 1,274.535 million against INR 1,091.004 million a year ago. Total income from operations was INR 1,309.619 million against INR 1,094.807 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 232.928 million against INR 230.246 million a year ago. Profit from ordinary activities before tax was INR 250.827 million against INR 257.475 million a year ago. Net profit for the period was INR 220.361 million against INR 223.747 million a year ago. Basic and diluted earnings per share before and after extraordinary activities were INR 8.12 against INR 8.25 diluted earnings per share before and after extraordinary activities a year ago. For the quarter, on consolidated basis, the company reported net sales/income from operations of INR 1,671.534 million against INR 1,463.006 million a year ago. Total income from operations was INR 1,680.708 million against INR 1,463.380 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 270.219 million against INR 255.187 million a year ago. Profit from ordinary activities before tax was INR 220.159 million against INR 220.104 million a year ago. Net profit for the period was INR 164.998 million against INR 157.303 million a year ago. Diluted earnings per share before and after extraordinary activities were INR 6.08 against INR 5.69 basic and diluted earnings per share before and after extraordinary activities a year ago. EBITDA grew 6% to INR 3,352.22 million from INR 3,156.81 million in the same quarter last year. For the six month, on consolidated basis, the company reported net sales/income from operations of INR 3,149.353 million against INR 2,700.888 million a year ago. Total income from operations was INR 3,167.648 million against INR 2,701.623 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 547.486 million against INR 468.065 million a year ago. Profit from ordinary activities before tax was INR 452.770 million against INR 389.908 million a year ago. Net profit for the period was INR 349.895 million against INR 287.858 million a year ago. Diluted earnings per share before and after extraordinary activities were INR 12.90 against INR 10.44 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNP:IN 778.15 INR 0.00

GLENMARK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ANI Pharmaceuticals Inc $54.54 USD -0.70
Impax Laboratories Inc $31.99 USD +0.67
Jubilant Life Sciences Ltd 119.45 INR 0.00
Lannett Co Inc $42.13 USD -0.16
Ranbaxy Laboratories Ltd 614.85 INR 0.00
View Industry Companies
 

Industry Analysis

GLENMARK

Industry Average

Valuation GLENMARK Industry Range
Price/Earnings 33.8x
Price/Sales 3.2x
Price/Book 6.6x
Price/Cash Flow 23.9x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLENMARK PHARMACEUTICALS LTD, please visit www.glenmarkpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.